Enrollment completed ahead of schedule in the global IDE for Abbott (ABT)'s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ ...
Abbott Laboratories' second-generation pulse field ablation device for atrial fibrillation has received European CE Mark approval earlier than expected, the North Chicago-based company said today. The ...
Abbott’s Volt™ PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses high energy ...
Announcing major milestones for the company’s suite of pulse field ablation (PFA) devices in electrophysiology, Abbott Laboratories said it is advancing treatment for patients with abnormal heart ...
Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results